Renal infarction Medical Services in China

Renal infarction is a rare but potentially serious condition characterized by ischemic necrosis of renal parenchyma due to abrupt occlusion of the renal artery or its branches—most commonly from embolic or thrombotic events. Unlike chronic renal ischemia, renal infarction presents acutely and demands prompt recognition to prevent irreversible loss of renal function, systemic complications (e.g., hypertension, acute kidney injury), or septic sequelae if infarcted tissue becomes infected. Pathogenesis centers on vascular obstruction: emboli—often originating from atrial fibrillation, valvular heart disease, or left ventricular thrombi—account for ~60–70% of cases; in situ thrombosis may occur in settings of vasculitis (e.g., polyarteritis nodosa), hypercoagulable states (e.g., antiphospholipid syndrome, malignancy), or trauma-related arterial injury. Less common causes include renal artery dissection, fibromuscular dysplasia, or paradoxical embolism via patent foramen ovale. Epidemiologically, renal infarction is underdiagnosed, with an estimated incidence of 0.03–0.1% among hospitalized adults undergoing abdominal imaging; it peaks in the sixth to seventh decades, with slight male predominance. Risk factors include cardiovascular comorbidities (atrial fibrillation, recent myocardial infarction, mechanical heart valves), inherited or acquired thrombophilias, active malignancy, endocarditis, and prior history of systemic embolism. Clinical presentation is highly variable: up to 30% of cases are asymptomatic and detected incidentally on CT or MRI; symptomatic patients typically present with sudden-onset flank or abdominal pain (often unilateral), low-grade fever, nausea, hematuria, and elevated lactate dehydrogenase (LDH) or D-dimer. Serum creatinine may remain normal initially—even with substantial infarct volume—making imaging (contrast-enhanced CT or MRI) essential for diagnosis. Delayed diagnosis increases risks of chronic kidney disease progression, hypertension secondary to renin-mediated activation, and reduced quality of life due to persistent pain, fatigue, anxiety about recurrent events, and limitations in physical activity or employment. Patients often experience significant psychological burden—including health-related anxiety and uncertainty—especially when underlying cardiac or thrombotic conditions require lifelong anticoagulation and multidisciplinary follow-up. Early intervention improves renal salvage potential, though functional recovery depends on infarct size, collateral circulation, and timeliness of reperfusion strategies. Long-term management emphasizes secondary prevention: anticoagulation (e.g., DOACs or warfarin), cardiovascular risk optimization, and surveillance for recurrence or contralateral involvement.

Renal infarction is a rare but potentially serious condition characterized by ischemic necrosis of renal parenchyma due to abrupt occlusion of one or more segmental or lobar branches of the renal artery. It accounts for <0.1% of all acute kidney injuries but carries significant morbidity if undiagnosed or mismanaged. The pathophysiology centers on thromboembolic or in situ thrombotic occlusion, with emboli originating most commonly from the heart or proximal aorta. Atrial fibrillation is the single most frequent underlying cardiac source, responsible for approximately 40–50% of documented cases; other cardiac etiologies include recent myocardial infarction (especially with left ventricular thrombus), infective endocarditis, mechanical or bioprosthetic heart valves, dilated cardiomyopathy, and atrial myxoma. Non-cardiac embolic sources include aortic atheroembolism—particularly from ulcerated plaques in the descending thoracic or abdominal aorta—and paradoxical embolism via patent foramen ovale in patients with deep vein thrombosis or pelvic malignancy. In situ renal artery thrombosis occurs less frequently but is strongly associated with hypercoagulable states (e.g., antiphospholipid syndrome, factor V Leiden, prothrombin G20210A mutation), vasculitides (e.g., polyarteritis nodosa, granulomatosis with polyangiitis, systemic lupus erythematosus), and iatrogenic injury during endovascular procedures such as angiography, stent placement, or partial nephrectomy. Traumatic dissection or compression of the renal artery (e.g., by retroperitoneal hematoma or tumor) may also precipitate infarction.

Triggers are typically acute hemodynamic or procedural events that unmask latent vulnerability. These include rapid cardioversion in longstanding atrial fibrillation (increasing embolic risk during early sinus rhythm), initiation or interruption of anticoagulation therapy, dehydration-induced hemoconcentration, postoperative immobility, acute infection (which promotes endothelial activation and coagulation cascade upregulation), and strenuous physical exertion in individuals with undiagnosed structural heart disease or severe atherosclerosis. Sudden hypotension or shock may exacerbate ischemia in kidneys already compromised by stenotic or embolized vessels.

Established risk factors encompass both modifiable and non-modifiable domains. Cardiovascular comorbidities predominate: hypertension (present in >70% of cases), coronary artery disease, congestive heart failure, and prior stroke or transient ischemic attack. Chronic kidney disease (CKD) stages 3–4 independently increases risk due to endothelial dysfunction, accelerated vascular calcification, and heightened platelet reactivity. Advanced age (>60 years), male sex (2:1 male-to-female ratio), diabetes mellitus, smoking, and obesity further amplify susceptibility through synergistic effects on arterial stiffness, inflammation, and thrombogenesis. Notably, patients with autosomal dominant polycystic kidney disease (ADPKD) face elevated risk—not only due to inherent vascular fragility and intrarenal aneurysms but also because cyst expansion can compress adjacent arterial branches, predisposing to localized infarction.

Genetic factors contribute significantly to thrombophilia-related renal infarction. Hereditary thrombophilias—including factor V Leiden (activated protein C resistance), prothrombin gene mutation (G20210A), methylenetetrahydrofolate reductase (MTHFR) polymorphisms (especially when coupled with hyperhomocysteinemia), and deficiencies in natural anticoagulants (antithrombin III, protein C, protein S)—confer lifelong hypercoagulability. Antiphospholipid syndrome, though often acquired, has strong genetic associations with HLA-DR4, HLA-DR7, and HLA-DRw9 alleles and may manifest familial clustering. Rare monogenic disorders such as hereditary hemorrhagic telangiectasia (HHT) increase risk via pulmonary arteriovenous malformations enabling paradoxical embolization.

Environmental and lifestyle exposures modulate risk substantially. Prolonged immobilization (e.g., long-haul air travel, hospitalization, spinal cord injury) promotes venous stasis and secondary embolism. Exposure to estrogen-containing medications—including combined oral contraceptives and hormone replacement therapy—exerts prothrombotic effects, particularly in carriers of thrombophilic mutations. Air pollution (PM2.5 and nitrogen dioxide) is increasingly linked to endothelial injury, oxidative stress, and platelet activation, contributing to arterial thrombosis. Occupational exposure to nephrotoxic solvents (e.g., carbon tetrachloride, trichloroethylene) may compound microvascular injury, while chronic heavy metal exposure (e.g., lead, cadmium) accelerates renal vascular remodeling and intimal hyperplasia. Socioeconomic determinants—including limited access to primary care, delayed anticoagulation initiation, and suboptimal management of hypertension or diabetes—also function as critical environmental modifiers of incidence and outcomes.

Renal infarction is a rare but potentially serious condition resulting from abrupt cessation of blood flow to a segment or the entirety of the kidney, most commonly due to embolism (e.g., from atrial fibrillation, valvular heart disease, or mural thrombus) or in situ thrombosis (e.g., in vasculitis, antiphospholipid syndrome, or renal artery dissection). Although historically underrecognized due to nonspecific presentation and diagnostic challenges, timely identification is critical to preserve renal parenchyma, prevent hypertension, and mitigate long-term sequelae such as chronic kidney disease or renovascular hypertension.

Early symptoms are frequently subtle and nonspecific, contributing to diagnostic delay. Patients may report acute-onset, unilateral flank or abdominal discomfort—often described as dull, aching, or pressure-like—rather than sharp colicky pain typical of nephrolithiasis. Low-grade fever (37.5–38.5°C) may be present in up to 40% of cases, reflecting localized inflammatory response and infarct-related cytokine release. Mild nausea, anorexia, or vague malaise may precede more definitive manifestations by hours to 2 days. Importantly, approximately 20–30% of patients remain asymptomatic initially, with infarction detected incidentally on imaging performed for unrelated indications—particularly in elderly or immunocompromised individuals with blunted pain perception or comorbid conditions masking symptomatology.

Typical symptoms emerge within 6–48 hours post-occlusion and reflect ischemic injury and capsular stretch. The hallmark is sudden, unilateral, severe flank pain—often radiating to the ipsilateral groin or anterior abdomen—accompanied by tenderness on deep palpation over the costovertebral angle. Hematuria (microscopic or gross) occurs in 50–70% of cases, typically non-dysuric and without clots, resulting from tubular epithelial necrosis and glomerular capillary disruption. Hypertension may develop acutely due to activation of the intrarenal renin-angiotensin-aldosterone system (RAAS), particularly if the infarct involves juxtaglomerular apparatus-rich cortical tissue; systolic blood pressure elevation >20 mmHg above baseline is common. In larger infarcts (>25% of renal volume), transient oliguria or decreased creatinine clearance may occur, though overt anuria is exceedingly rare unless bilateral involvement or preexisting renal impairment exists.

Accompanying symptoms further support the diagnosis and suggest underlying etiology. Dyspnea or palpitations may point to a cardioembolic source (e.g., new-onset atrial fibrillation or recent myocardial infarction). Skin manifestations—including livedo reticularis, digital infarcts, or splinter hemorrhages—raise suspicion for systemic vasculitis (e.g., polyarteritis nodosa) or hypercoagulable states. Neurological symptoms (e.g., transient ischemic attack, aphasia) warrant urgent cardiac and carotid evaluation for paradoxical embolism or shared thromboembolic risk. Laboratory abnormalities often include leukocytosis (WBC 10–15 × 10⁹/L) without left shift, mild elevations in lactate dehydrogenase (LDH) and aspartate aminotransferase (AST), and occasionally elevated D-dimer—though the latter lacks specificity and may be normal in small or subacute infarcts. Urinalysis typically reveals hematuria ± mild proteinuria (<1 g/day); pyuria is uncommon unless superimposed infection or vasculitic glomerulonephritis coexists.

Complications arise from both the infarct itself and its underlying cause. Infarct extension may lead to cortical thinning, segmental atrophy, or development of a nonfunctioning renal scar—visible on follow-up imaging as wedge-shaped cortical defects. Persistent RAAS activation contributes to refractory hypertension, especially if untreated. Rarely, infarcted tissue undergoes liquefactive necrosis, forming a sterile perirenal abscess or spontaneous retroperitoneal hemorrhage. Embolic recurrence carries significant risk: up to 30% of untreated cardioembolic cases suffer subsequent stroke or mesenteric infarction within 3 months. Chronic complications include progressive decline in estimated glomerular filtration rate (eGFR), development of secondary hyperparathyroidism due to reduced renal 1α-hydroxylase activity, and increased cardiovascular mortality—particularly in patients with concomitant heart failure or atherosclerosis.

Diagnosis relies on high clinical suspicion combined with multimodal imaging. Contrast-enhanced computed tomography (CT) is the first-line modality, demonstrating classic wedge-shaped, non-enhancing cortical defects with intact medullary enhancement and preserved renal contour. Magnetic resonance angiography (MRA) offers superior soft-tissue contrast and avoids iodinated contrast, making it ideal in patients with contraindications to CT; diffusion-weighted imaging (DWI) shows restricted diffusion in acute infarcts (<72 hours). Renal Doppler ultrasound may reveal absent or diminished arterial flow in the affected segment, though it lacks sensitivity for small or hilar infarcts. Digital subtraction angiography remains the gold standard for detecting vascular occlusion and guiding potential endovascular intervention but is reserved for equivocal cases or therapeutic intent due to invasiveness and nephrotoxicity risk. Laboratory workup must include ECG (for arrhythmia), echocardiography (TTE/TEE for thrombus), coagulation profile (PT/aPTT, factor V Leiden, antithrombin III, lupus anticoagulant), and serologic testing for ANCA, ANA, and complement levels when vasculitis is suspected.

Differential diagnosis is broad and requires careful exclusion. Acute pyelonephritis presents with fever, costovertebral angle tenderness, and pyuria—but demonstrates diffuse or patchy enhancement on CT and responds to antibiotics. Nephrolithiasis causes colicky pain, hematuria, and often hydronephrosis on ultrasound/CT, with no perfusion defect. Renal vein thrombosis manifests with flank pain, hematuria, and proteinuria—often with nephrotic-range proteinuria and renal enlargement; CT venography confirms filling defects in the renal vein. Segmental arterial obstruction from fibromuscular dysplasia or atherosclerotic stenosis typically causes chronic, progressive hypertension and ischemic atrophy rather than acute infarction. Autoimmune tubulointerstitial nephritis (e.g., Sjögren’s-associated) may mimic painless renal dysfunction but lacks imaging evidence of infarction and shows characteristic interstitial infiltrates on biopsy. Finally, renal cell carcinoma can rarely present with paraneoplastic flank pain and hematuria, but demonstrates a solid, enhancing mass—not a non-enhancing wedge—on cross-sectional imaging. Accurate differentiation hinges on integrating temporal profile, imaging morphology, laboratory findings, and comprehensive cardiovascular and rheumatologic assessment.

Renal infarction is a rare but potentially serious condition resulting from abrupt occlusion of the renal artery or its branches—most commonly due to embolism (e.g., from atrial fibrillation, valvular heart disease, or left ventricular thrombus), thrombosis (e.g., in vasculitis, antiphospholipid syndrome, or hypercoagulable states), or less frequently, trauma or iatrogenic injury. Clinical presentation is often nonspecific and may include acute flank or abdominal pain, fever, hematuria, elevated serum lactate dehydrogenase (LDH), and rising creatinine—though up to 30% of cases are asymptomatic and detected incidentally on imaging. Prompt diagnosis via contrast-enhanced CT angiography or MRI is critical, as delayed intervention risks irreversible cortical necrosis, hypertension secondary to renin-mediated activation, and progressive chronic kidney disease.

Conservative management is appropriate for hemodynamically stable patients with small, peripheral infarcts (<25% of renal volume), preserved renal function, and no evidence of ongoing embolic source or systemic complications. This approach emphasizes close monitoring of vital signs, serial renal function tests (serum creatinine, estimated GFR, electrolytes), urinalysis, and inflammatory markers (CRP, LDH). Serial abdominal ultrasound with Doppler may assess perfusion changes, though it lacks sensitivity for early cortical infarction. Bed rest, adequate hydration (unless contraindicated by heart failure), and strict blood pressure control (target <130/80 mmHg) are foundational. Importantly, conservative care must be coupled with rigorous identification and mitigation of the underlying etiology—e.g., echocardiography to exclude intracardiac thrombus, screening for autoimmune vasculitides (ANCA, ANA, complement levels), and thrombophilia workup (factor V Leiden, prothrombin gene mutation, protein C/S, antithrombin III, lupus anticoagulant).

Pharmacotherapy is central to both acute management and long-term prevention. Anticoagulation is indicated in nearly all non-contraindicated cases: intravenous unfractionated heparin is initiated immediately for suspected embolic infarction, followed by transition to oral anticoagulants—preferably direct oral anticoagulants (DOACs) such as apixaban, rivaroxaban, or edoxaban in patients with non-valvular atrial fibrillation, given their favorable safety profile and reduced bleeding risk versus warfarin. Warfarin remains first-line for mechanical heart valves or antiphospholipid syndrome (target INR 2.5–3.5). Antiplatelet agents (e.g., aspirin or clopidogrel) are generally insufficient as monotherapy but may be added in select cases of arterial thrombosis with underlying atherosclerosis. Analgesia should avoid NSAIDs due to nephrotoxicity and prostaglandin-mediated renal vasoconstriction; acetaminophen or low-dose opioids are preferred. Hypertension is managed with ACE inhibitors or ARBs if eGFR >30 mL/min/1.73m² and potassium <5.0 mmol/L—these agents also attenuate intrarenal renin-angiotensin system activation post-infarction. Statins are recommended for secondary cardiovascular prevention, particularly in patients with concomitant atherosclerotic disease.

Surgical or endovascular intervention is reserved for select high-risk scenarios: hemodynamic instability, bilateral or solitary kidney involvement, progressive renal dysfunction despite anticoagulation, or large infarcts (>50% volume) with impending cortical loss. Catheter-directed thrombolysis (e.g., intra-arterial alteplase) may be considered within 6–12 hours of symptom onset in experienced centers, though evidence is limited to case series and carries significant bleeding risk. Mechanical thrombectomy using aspiration catheters or stent retrievers has emerging utility in proximal main renal artery occlusion, especially when thrombolysis is contraindicated. Surgical embolectomy is rarely performed today but remains an option in centers without interventional radiology capability or in cases of massive embolism with rapid deterioration. Nephrectomy is a last resort—indicated only for uncontrolled pain, persistent infection (infected infarct), hemorrhage, or refractory hypertension unresponsive to medical therapy.

China offers distinct advantages in the multidisciplinary management of renal infarction. First, integrated vascular medicine–nephrology–interventional radiology teams at Tier-3 hospitals (e.g., Peking University First Hospital, Shanghai Renji Hospital) enable rapid triage, same-day advanced imaging, and 24/7 endovascular capability. Second, China’s national anticoagulation registries and AI-assisted decision support tools improve DOAC selection, dosing accuracy, and bleeding risk stratification—reducing adverse events by ~22% compared to conventional protocols. Third, standardized clinical pathways endorsed by the Chinese Society of Nephrology emphasize early echocardiographic screening and thrombophilia testing, leading to higher rates of etiologic diagnosis (89% vs. global average ~72%). Fourth, cost-effective access to generic DOACs and domestically manufactured thrombolytics enhances treatment adherence, particularly in rural referral networks linked via tele-nephrology platforms. Finally, China’s robust traditional medicine integration programs permit evidence-based adjunctive use of herbs like Salvia miltiorrhiza (Danshen), which demonstrates anti-thrombotic and microcirculatory improvement effects in preclinical models—though used strictly as adjuvant therapy under nephrologist supervision.

Recovery requires structured, longitudinal follow-up. Patients should undergo renal function assessment every 2 weeks for the first month, then monthly for 3 months, and quarterly thereafter. Imaging (Doppler ultrasound or low-dose CT) is repeated at 3 and 6 months to evaluate infarct resolution and compensatory hypertrophy. Blood pressure must be monitored daily at home; home BP logs facilitate timely RAAS inhibitor titration. Lifestyle modifications are essential: smoking cessation, sodium restriction (<2 g/day), moderate protein intake (0.8 g/kg/day if eGFR <60), and aerobic exercise (≥150 min/week) to mitigate cardiovascular risk. Vaccination against influenza and pneumococcus is strongly advised due to heightened infection susceptibility post-acute ischemic injury. Psychosocial support—including counseling for anxiety related to recurrent thromboembolism—is increasingly embedded in Chinese nephrology outpatient programs. Long-term anticoagulation duration depends on etiology: lifelong for mechanical valves or antiphospholipid syndrome; indefinite for unprovoked embolism with persistent atrial fibrillation; and time-limited (3–6 months) for provoked, reversible causes (e.g., postoperative hypercoagulability). With timely diagnosis and protocol-driven care, over 85% of patients maintain stable renal function at 1-year follow-up, underscoring the importance of early nephrology referral and systematic secondary prevention.